Molecular Analysis-Based Treatment Strategies for Non–Small Cell Lung Cancer
Authors:
Open Access
- 1 April 2008
- journal article
- research article
- Published by SAGE Publications in Cancer Control
- Vol. 15 (2) , 130-139
Abstract
Lung cancer is the leading cause of cancer-related mortality. Improved understanding in the molecular biology and genetics of lung cancer has resulted in the identification of individual genes, gene expression profiles, and molecular pathways that may be useful for clinical management decisions. We focused on recent molecules and platforms under evaluation for implementation into clinical decision making. Prognostic molecular parameters are defined as markers that impact overall outcome in terms of survival independent of therapeutic interventions. Predictive molecular parameters are defined as markers that impact therapeutic efficacy. Several molecules and profiles are emerging with promising utility as predictive and prognostic parameters in non–small cell lung cancer independent of the standard clinical parameters, such as stage, performance status, and gender. These include the genes ERCC1, RRM1, and BRCA1, which are involved in nucleotide metabolism and DNA damage repair, epidermal growth factor receptor, which is involved in cell proliferation and survival, and oligonucleotide expression array profiles, which are signatures of global gene expression associated with specific tumor phenotypes.Keywords
This publication has 33 references indexed in Scilit:
- BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung CancerPLOS ONE, 2007
- Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional StudyJNCI: Journal of the National Cancer Institute, 2007
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Selective Profiling of Proteins in Lung Cancer Cells from Fine-Needle Aspirates by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass SpectrometryClinical Cancer Research, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell LinesCancer Research, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Ribonucleotide reductase: regulation, regulation, regulationTrends in Biochemical Sciences, 1992